Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Skin Biopsy

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Completed2
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06545695Phase 1/2Not Yet RecruitingPrimary

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

NCT05312073Not ApplicableCompleted

Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis

NCT03041038Phase 2Completed

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Showing all 3 trials

Research Network

Common Treatments

  • Skin Biopsy1
  • Erlotinib1
  • Secukinumab1
  • Biological Samples1

Active Sponsors

  • Northwestern University2
  • Yale University1
  • Assistance Publique - Hôpitaux de Paris1
  • Icahn School of Medicine at Mount Sinai1

Top Investigators

Related Conditions

  • Autosomal Recessive Congenital Ichthyosis2
  • Lamellar Ichthyosis1
  • Netherton Syndrome1
  • Pachyonychia Congenita1
  • Congenital Ichthyosiform Erythroderma1

Activity Timeline